| EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update JS Smolen, R Landewé, J Bijlsma, G Burmester, K Chatzidionysiou, ... Annals of the rheumatic diseases 76 (6), 960-977, 2017 | 6027 | 2017 |
| EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update JS Smolen, RBM Landewé, JWJ Bijlsma, GR Burmester, M Dougados, ... Annals of the rheumatic diseases 79 (6), 685-699, 2020 | 2864 | 2020 |
| EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update JS Smolen, RBM Landewé, SA Bergstra, A Kerschbaumer, A Sepriano, ... Annals of the rheumatic diseases 82 (1), 3-18, 2023 | 1075 | 2023 |
| Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis P Domingo, I Mur, GM Mateo, M del Mar Gutierrez, V Pomar, N de Benito, ... Jama 326 (6), 499-518, 2021 | 529 | 2021 |
| Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results … RF Van Vollenhoven, S Ernestam, P Geborek, IF Petersson, L Cöster, ... The Lancet 374 (9688), 459-466, 2009 | 431 | 2009 |
| Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis S Ramiro, A Sepriano, K Chatzidionysiou, JL Nam, JS Smolen, ... Annals of the rheumatic diseases 76 (6), 1093-1101, 2017 | 383 | 2017 |
| Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has … K Chatzidionysiou, E Lie, E Nasonov, G Lukina, ML Hetland, U Tarp, ... Annals of the rheumatic diseases 70 (9), 1575-1580, 2011 | 322 | 2011 |
| Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of … JL Nam, K Takase-Minegishi, S Ramiro, K Chatzidionysiou, JS Smolen, ... Annals of the rheumatic diseases 76 (6), 1113-1136, 2017 | 295 | 2017 |
| Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel … RF van Vollenhoven, P Geborek, K Forslind, K Albertsson, S Ernestam, ... The Lancet 379 (9827), 1712-1720, 2012 | 289 | 2012 |
| Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature E Nikiphorou, H Radner, K Chatzidionysiou, C Desthieux, C Zabalan, ... Arthritis research & therapy 18, 1-11, 2016 | 266 | 2016 |
| Delays in assessment of patients with rheumatoid arthritis: variations across Europe K Raza, R Stack, K Kumar, A Filer, J Detert, H Bastian, GR Burmester, ... Annals of the rheumatic diseases 70 (10), 1822-1825, 2011 | 205 | 2011 |
| Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR … K Chatzidionysiou, S Emamikia, J Nam, S Ramiro, J Smolen, ... Annals of the rheumatic diseases 76 (6), 1102-1107, 2017 | 150 | 2017 |
| Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year … K Chatzidionysiou, E Lie, E Nasonov, G Lukina, ML Hetland, U Tarp, ... Annals of the rheumatic diseases 71 (3), 374-377, 2012 | 126 | 2012 |
| Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study C Gabay, M Riek, ML Hetland, EM Hauge, K Pavelka, M Tomšič, ... Annals of the rheumatic diseases 75 (7), 1336-1342, 2016 | 102 | 2016 |
| Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study H Bower, T Frisell, D Di Giuseppe, B Delcoigne, GM Ahlenius, ... Annals of the rheumatic diseases 80 (8), 1086-1093, 2021 | 98 | 2021 |
| Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register K Chatzidionysiou, J Askling, J Eriksson, LE Kristensen, ... Annals of the rheumatic diseases 74 (5), 890-896, 2015 | 97 | 2015 |
| The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries DS Courvoisier, K Chatzidionysiou, D Mongin, K Lauper, X Mariette, ... Rheumatology 60 (2), 820-828, 2021 | 85 | 2021 |
| Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis V Molander, H Bower, T Frisell, B Delcoigne, D Di Giuseppe, J Askling, ... Annals of the Rheumatic Diseases 82 (2), 189-197, 2023 | 75 | 2023 |
| Disease activity patterns over time in patients with SLE: analysis of the Hopkins Lupus Cohort N Györi, I Giannakou, K Chatzidionysiou, L Magder, RF Van Vollenhoven, ... Lupus science & medicine 4 (1), e000192, 2017 | 72 | 2017 |
| 2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis H Radner, K Chatzidionysiou, E Nikiphorou, L Gossec, KL Hyrich, ... Annals of the rheumatic diseases 77 (4), 476-479, 2018 | 71 | 2018 |
